10:18 AM EDT, 05/21/2025 (MT Newswires) -- Protagenic Therapeutics ( PTIX ) said Wednesday that warrant exchanges and exercises in the past four business days yielded $3.1 million in cash.

The proceeds will be used to fund working capital and advance Protagenic's peptide-based drug candidates for stress and central-nervous-system disorders, according to a statement.

Meanwhile, the company said it executed a business combination with Phytanix Bio, integrating six programs under one company.

Price: 6.91, Change: +0.03, Percent Change: +0.39